Articles

A-108 Belgian multicenter study into von Willebrand Disease (B-Will Study): First results

BJH - 2014, issue Abstract Book BSTH, november 2014

I. Vangenechten , K. Jochmans MD, PhD, P. Péters , K. Devreese , C. Hermans MD, PhD, S. Motte , A. Gadisseur MD, PhD

Read more

The Use of Temporary Central Venous Catheters for Optimizing Continuous Infusion in Hemophilia Patients Undergoing Major Surgical Procedures

BJH - 2014, issue Abstract Book BSTH, november 2014

A. Boban , C. Lambert MD, C. Hermans MD, PhD

Read more

Value and implications of the anti-Xa activity monitoring in pregnant women receiving prophylactic LMWH: a retrospective study

BJH - 2014, issue Abstract Book BSTH, november 2014

S. Paulus , A. Boban , C. Lambert MD, C. Hermans MD, PhD

Read more

Treatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society

BJH - volume 5, issue 3, september 2014

E. Mourin MD, A. Van Hoof MD, PhD, A. Bosly MD, PhD, C. Bonnet MD, PhD, V. De Wilde MD, PhD, C. Doyen MD, PhD, C. Hermans MD, PhD, A. Janssens MD, PhD, L. Michaux MD, PhD, W. Schroyens MD, PhD, A. Sonet MD, E. Van den Neste MD, PhD, G. Verhoef MD, PhD, P. Zachée MD, PhD, M. André MD

Summary

Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) translocation which results in overexpression of cyclin D1.1 This disease represents approximately 6% of all non-Hodgkin’s lymphomas. Mantle cell lymphoma generally affects patients over 60 years-old. Most patients have advanced disease (>70 % Ann Arbor stage IV). Several efforts have been made to predict outcome in mantle cell lymphoma. The cell-proliferation marker Ki-67, the Mantle Cell Lymphoma International Prognostic Index, fluorodeoxyglucose positron emission tomography and minimal residual disease are prognostic tools. For young patients, chemoimmunotherapy followed by high-dose chemotherapy plus stem cell transplantation is the treatment of choice. For the main group of older patients, chemo-immunotherapy followed by maintenance with rituximab is the gold standard. In relapses, temsirolimus is actually registered and new drugs, such as ibrutinib, are currently evaluated with promising preliminary results.2–5

(BELG J HEMATOL 2014;5(3):89–96)

Read more

Old and new anticoagulants in practice

BJH - volume 5, issue Abstract Book BHS, january 2014

C. Hermans MD, PhD

Read more

Functional assessment of haemophilic arthropathy with three-dimensional gait analysis

BJH - volume 4, issue 2, june 2013

S. Lobet PhD, C. Hermans MD, PhD

Summary

In patients with haemophilia, the long-term consequences of repeated haemarthrosis include joint cartilage damage and irreversible chronic arthropathy, resulting in severe impairments in locomotion. Quantifying the extent of joint damage is of paramount importance in order to prevent disease progression and compare the efficacy of treatment strategies, such as prophylaxis. Here we summarise the results of several studies establishing three-dimensional gait analysis as an innovative approach to evaluate functionally haemophilic arthropathy. This work also provides new insights into the understanding of the biome-chanical consequences of haemophilic arthropathy.

(BELG J HEMATOL 2013;4(2):72–76)

Read more